Actually, in a preliminary experiment, CAR-T cells were administered without IL-2 support, and neither of the two CAR-T groups exhibited anti-tumor activity (data not shown), suggesting that IL-2 indeed serves a pivotal role in enhancing the in vivo survival and functionality of CAR-T cells [38]. The gene discussed is IL2; the disease is neoplasm.